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Neutralising antibodies recognising membrane proximal
epitopes of gp41 have been isolated from HIV-infected
patients. Since these epitope domains are highly con-
served, the corresponding antibodies 2F5 and 4E10 neu-
tralise a broad range of HIV strains. Numerous attempts
by several laboratories to generate 2F5/4E10-like antibod-
ies by vaccination have failed, obviously because the con-
formation of the domain is difficult to reproduce.
Recently we reported induction of neutralising antibodies
against the porcine endogenous retrovirus (PERV) and the
feline leukaemia virus (FeLV) by immunisation with their
transmembrane envelope (TM) proteins p15E. In both
retroviral TM proteins two epitope regions were identi-
fied, one located in the N-terminal part (designated E1)
and the other located in the C-terminal part of p15E (E2).
E2 is related to the 2F5/4E10-epitope, and is located
opposite E1 when the TM envelope protein has folded. An
E1 domain was identified in the C-terminal part of gp41
and two strategies were developed to induce neutralising
antibodies against HIV. First, immunisation was per-
formed with a hybrid protein based on p15E of PERV,
containing the E1 domain and the E2 (2F5/4E10 epitope)
domain of gp41 of HIV-1. Second, immunisation was per-
formed with a hybrid containing the N-terminal back-
bone of p15E of FeLV and only the E2 (2F5/4E10 epitope)
domain of gp41. With both strategies antibodies neutral-
ising laboratory and primary strains of HIV-1 were
induced. These strategies may be used to generate a vac-
cine inducing broadly neutralising antibodies to prevent
or curtail HIV infection.
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